Quest Partners LLC Buys 3,549 Shares of DexCom, Inc. (NASDAQ:DXCM)

Quest Partners LLC increased its position in DexCom, Inc. (NASDAQ:DXCM) by 473.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,298 shares of the medical device company’s stock after buying an additional 3,549 shares during the period. Quest Partners LLC’s holdings in DexCom were worth $487,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New Hampshire acquired a new stake in DexCom in the first quarter valued at approximately $1,508,000. Eagle Asset Management Inc. increased its stake in DexCom by 21.5% during the 4th quarter. Eagle Asset Management Inc. now owns 1,756,216 shares of the medical device company’s stock valued at $217,929,000 after purchasing an additional 310,728 shares in the last quarter. Alberta Investment Management Corp raised its holdings in DexCom by 27.0% during the fourth quarter. Alberta Investment Management Corp now owns 323,335 shares of the medical device company’s stock worth $40,123,000 after buying an additional 68,723 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares in the last quarter. Finally, Los Angeles Capital Management LLC grew its holdings in shares of DexCom by 62.5% during the first quarter. Los Angeles Capital Management LLC now owns 357,033 shares of the medical device company’s stock valued at $49,520,000 after buying an additional 137,336 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

Shares of DXCM opened at $68.82 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The firm has a market cap of $27.37 billion, a PE ratio of 44.40, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock’s fifty day moving average price is $83.24 and its two-hundred day moving average price is $111.61.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company’s revenue was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.34 earnings per share. On average, equities research analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 2,483 shares of company stock worth $201,708. 0.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several recent research reports. Redburn Atlantic initiated coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. BTIG Research lowered their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Morgan Stanley cut their price objective on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating on the stock in a report on Friday, July 26th. Finally, JPMorgan Chase & Co. lowered shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $145.00 to $75.00 in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.